Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNA5 | P22460 | 10/20 | 0.40 |
| ▸ | KCNN4 | O15554 | 7/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | LMNA | P02545 | 3/20 | 0.32 |
| ▸ | GAA | P10253 | 2/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.31 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.30 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23911696 | 0.86 | LMNA (0.43) | KCNA5KCNN4LMNAGAAKMT2A | |
| SCHEMBL23911731 | 0.75 | LMNA (0.36) | ALDH1A1LMNAGAAKMT2AMAPT | |
| SCHEMBL23911733 | 0.72 | LMNA (0.44) | KCNA5KCNN4LMNAGAAKMT2A | |
| SCHEMBL23911740 | 0.69 | LMNA (0.33) | ALDH1A1LMNAGAAKMT2AMAPT | |
| SCHEMBL19721596 | 0.69 | ALDH1A1 (0.43) | ALDH1A1LMNAKMT2AMAPTHTT | |
| SCHEMBL23911734 | 0.68 | LMNA (0.40) | KCNA5KCNN4ALDH1A1LMNAGAA | |
| SCHEMBL23911738 | 0.67 | LMNA (0.41) | KCNA5KCNN4ALDH1A1LMNAGAA | |
| SCHEMBL25310546 | 0.66 | LMNA (0.51) | ALDH1A1LMNAGAAMAPTHTT | |
| SCHEMBL22160113 | 0.65 | ALDH1A1 (0.42) | ALDH1A1CYP19A1CYP2D6CYP2C9 | |
| SCHEMBL29892532 | 0.65 | ALDH1A1 (0.42) | ALDH1A1CYP19A1CYP2D6CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220020937-A1 | HETEROCYCLIC COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE INCLUDING THE SAME | SAMSUNG DISPLAY CO., LTD. (KR) | 2022-01-20 | — | — | US | disclosed |
| US-11145823-B2 | Heterocyclic compound and organic light emitting device including the same | SAMSUNG DISPLAY CO., LTD. (KR) | 2021-10-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11145823-B2 | Heterocyclic compound and organic light emitting device including the same | TRPC1, ODC1, DDT | KCNA5 773/4885KCNN4 126/4885ALDH1A1 48/4885 |
| US-20220020937-A1 | HETEROCYCLIC COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE INCLUDING THE SAME | TRPC1, ODC1, DDT | KCNA5 578/4885KCNN4 79/4885ALDH1A1 63/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.